R&D channel feed – Endpoints News

R&D channel feed

Unfazed by PhII miss, Roche ushers Prothena's Parkinson's drug into late-stage trial — a $60M move

5 years ago

CRISPR Therapeutics gets a snapshot of off-the-shelf CAR-T success in B-cell malignancies — marred by the death of a patient

5 years ago

Left for dead after a failure in neuropathic pain, Aptinyx latches onto positive PhII data in PTSD

5 years ago

After nearly a year of debate, the Covid-19 vaccine challenge trials are officially coming

5 years ago

Super-secretive anti-aging biotech Calico tees up the first visible clinical trial of an experimental drug. And it’s for cancer?

5 years ago

RBC's Brian Abrahams holds a mock adcomm on Biogen's iffy aducanumab data — and most of these experts don't see a path to an approval

5 years ago

Merck touts new data for Keytruda combos in NSCLC at North American conference

5 years ago

European regulators spurn Agios' AML drug Tibsovo, unconvinced by the same thin PhI data that won over the FDA

5 years ago

Gilead feels the heat as close ally Galapagos reports a big setback on one of their top experimental drugs

5 years ago

Roche writes off ulcerative colitis portion of etrolizumab program, days after dissecting PhIII setback

5 years ago

The Sanofi/Translate team hits the green light on an early-stage study for their mRNA Covid-19 vaccine after seeing it work in animals

5 years ago

Patient death in pivotal gene therapy trial rattles Sarepta partner already facing clinical hold

5 years ago

Vertex shares take a hit as liver tox forces the research team to scrap a PhII drug for AAT patients. Will we see new deals now?

5 years ago

Cyclerion axes another program as struggles grow for Peter Hecht's Ironwood spinout

5 years ago

Pair of Lancet studies give final word on a promising Shionogi antibiotic that turned out to be 'as good' as the other 'suboptimal' options

5 years ago

Gossamer shares take another beating as its lead drug fails 2 key clinical studies, highlighting harsh reviews for DP2

5 years ago

Riding a PhII success, a small French biotech lands a rare 'breakthrough' status in NASH

5 years ago

Bob Langer-backed spinout shoots for $75M-plus IPO while biotech SPACs continue to rule on Wall Street

5 years ago

Lilly shows more positive Crohn's data for its IL-23 inhibitor as it continues to chase down rivals

5 years ago

Novartis vets get $35M to pluck one of the pharma giant’s abandoned drugs off the shelf and put it back into a clinical trial

5 years ago

Pfizer's last bid to reverse Lilly's CDK4/6 early-stage takeover fails, as a second Ibrance study falters

5 years ago

It's not just the antibodies: Eli Lilly burnishes its second EUA in play with new Covid-19 data on Olumiant plus remdesivir

5 years ago

Amgen's big cardiovascular bet with Cytokinetics hits PhIII primary but dramatically disappoints investors

5 years ago

In another PhIII, Albert Bourla continues to build case for a once-flopped GHD drug

5 years ago

First page Previous page 185 186 187188189 190 191 Next page Last page